Retina (Philadelphia, Pa.) · 2026
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR STAGES 3 AND 4 PROLIFERATIVE SICKLE CELL RETINOPATHY RESULTS IN IMPROVED ANATOMICAL AND VISUAL OUTCOMES.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lim Jennifer I, Okonkwo Ogugua N, Ong Sally S, Regillo Carl D, Scott Adrienne W, Wykoff Charles C, Cao Jessica, Chen Alicia, Miao Bernadette A, Momenaei Bita, Liu Jianyou
Аннотация
PURPOSE: To investigate the potential utility of intravitreal antivascular endothelial growth factor (anti-VEGF) therapy for stages 3 and 4 proliferative sickle cell retinopathy (PSR).
METHODS: Retrospective review of anatomical and visual acuity outcomes after intravitreal anti-VEGF therapy for stages 3 and 4 PSR eyes.
RESULTS: There were 45 PSR eyes (17 stage 3 and 28 stage 4) treated with anti-VEGF agents (bevacizumab (37 eyes), aflibercept (6 eyes), ranibizumab (3 eyes), one eye received both bevacizumab and aflibercept). Follow-up ranged from 1 to 120 months (mean = 21 months). Within 1 month after anti-VEGF treatment, VA improved ≥2 lines in 18/45 eyes, remained stable in 26/45 eyes, and worsened in 1/45 eyes. The median visual acuity remained 20/20 for stage 3 and improved from 20/200 to 20/30 for stage 4 PSR eyes. More stage 4 PSR eyes had VA improvement posttreatment than stage 3 PSR eyes ( P = 0.003). There were no cases of endophthalmitis. Visual acuity outcomes were similar for anti-VEGF with and without laser treatment. Control of PSR was achieved in 42/45 (93%) of eyes without the need for pars plana vitrectomy.
CONCLUSION: Within one month of treatment, administration of anti-VEGF therapy of PSR eyes resulted in seafan regression, clearing of vitreous hemorrhage, and stable or improved vision in most eyes.
METHODS: Retrospective review of anatomical and visual acuity outcomes after intravitreal anti-VEGF therapy for stages 3 and 4 PSR eyes.
RESULTS: There were 45 PSR eyes (17 stage 3 and 28 stage 4) treated with anti-VEGF agents (bevacizumab (37 eyes), aflibercept (6 eyes), ranibizumab (3 eyes), one eye received both bevacizumab and aflibercept). Follow-up ranged from 1 to 120 months (mean = 21 months). Within 1 month after anti-VEGF treatment, VA improved ≥2 lines in 18/45 eyes, remained stable in 26/45 eyes, and worsened in 1/45 eyes. The median visual acuity remained 20/20 for stage 3 and improved from 20/200 to 20/30 for stage 4 PSR eyes. More stage 4 PSR eyes had VA improvement posttreatment than stage 3 PSR eyes ( P = 0.003). There were no cases of endophthalmitis. Visual acuity outcomes were similar for anti-VEGF with and without laser treatment. Control of PSR was achieved in 42/45 (93%) of eyes without the need for pars plana vitrectomy.
CONCLUSION: Within one month of treatment, administration of anti-VEGF therapy of PSR eyes resulted in seafan regression, clearing of vitreous hemorrhage, and stable or improved vision in most eyes.
Предметные рубрики MeSH
HumansRetrospective StudiesVisual AcuityAngiogenesis InhibitorsMaleReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AFemaleIntravitreal InjectionsRanibizumabBevacizumabAdultAnemia, Sickle CellRecombinant Fusion ProteinsFollow-Up StudiesYoung AdultTomography, Optical CoherenceMiddle AgedTreatment OutcomeAdolescentRetinal NeovascularizationFluorescein AngiographyRetinal Diseases